Sovaldi (sofosbuvir) — United Healthcare

chronic hepatitis C genotype 1 or 4 in peginterferon eligible patients without cirrhosis or with compensated cirrhosis

Preferred products

Diagnosis of chronic hepatitis C genotype 1 infection OR Diagnosis of chronic hepatitis C genotype 4 infection
Patient has not experienced failure with a previous treatment regimen that includes Sovaldi
Used in combination with peginterferon alfa and ribavirin
Patient is without cirrhosis OR Patient has compensated cirrhosis (Child-Pugh A)
Physician/provider asserts patient demonstrates treatment readiness, including the ability to adhere to the treatment regimen
All of the following: History of intolerance or contraindication to Epclusa (sofosbuvir/velpatasvir) therapy AND History of intolerance or contraindication to Harvoni (sofosbuvir/ledipasvir) therapy AND History of intolerance or contraindication to Mavyret (glecaprevir/pibrentasvir) therapy AND History of intolerance or contraindication to Zepatier (elbasvir/grazoprevir) therapy OR Patient is currently on Sovaldi therapy

12 weeks